Image Place holder

Andreas N. Saltos, MD


Specialty: Hematology/Oncology
Program: Thoracic Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Types Treated: Lung Cancer , Mesothelioma , Pancoast Tumor

Dr. Andreas Saltos earned his MD from the University of Maryland School of Medicine in Baltimore. He completed his Internal Medicine Residency at the University of Maryland Medical Center in Baltimore before moving to Tampa, where he completed a Hematology and Medical Oncology Fellowship at the University of South Florida Morsani College of Medicine and Moffitt Cancer Center. Dr. Saltos specializes in the treatment of thoracic malignancies, including all forms and stages of lung cancer.  In his clinical practice he strives to match patients with the optimal treatments that are tailored to their specific cancer and individual needs.  The ability to work with an incredible cancer team and apply the latest advances to treat patients in the clinic is what makes him excited to work at Moffitt. He also dedicates a significant portion of his effort to research.  His focus is in clinical research aiming to find better treatments for lung cancers, including using new strategies for targeted therapy and immunotherapy.  He is currently leading and developing clinical trials investigating novel drugs or treatment combinations which either target the specific genetic features of lung cancers or recruit the immune system to combat cancer.  One of Dr. Saltos’ favorite speeches is by Jim Valvano at the 1993 ESPY awards, which he delivered during his battle with cancer.  He provides an insightful perspective on life and brings attention to the mission of cancer research; he closes with “Cancer can take away all my physical abilities. It cannot touch my mind, it cannot touch my heart and it cannot touch my soul. And those three things are going to carry on forever.”

Education & Training

Board Certification:

  • Internal Medicine

Fellowship:

  • University of South Florida Moffitt Cancer Center - Hematology and Medical Oncology

Residency:

  • University of Maryland Medical Center -

Medical School:

  • University of Maryland Medical Center - MD
Participating Trials

CLINICAL TRIAL 18398
Novartis Pharmaceuticals trial entitled: A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC)
Condition: Thoracic
Intervention: INC280 (Capmatinib)
Open

CLINICAL TRIAL 18304
A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
Condition: Thoracic
Intervention: AZD1775; MK-1775 (AZD1775); Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin; paclitaxel
Open

CLINICAL TRIAL 17908
Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Screening Step)
Condition: Thoracic
Intervention: 750009 (Rilotumumab); 765338 (AZD4547); 772256 (Palbociclib); AMG102 (Rilotumumab); AMP-514 (Durvalumab); AZD4547; BMN-673 (Talazoparib); BMS-936558 (Nivolumab); CP-675,206 (tremelimumab); Dexamethasone; Durvalumab; Erlotinib; GDC-0032 (Taselisib); Ipilimumab; MEDI4736 (Durvalumab); Nivolumab; Palbociclib; Rilotumumab; Talazoparib; Tarceva (Erlotinib); Taxotere (docetaxel); Yervoy (Ipilimumab); docetaxel; tremelimumab
Open

CLINICAL TRIAL 17970
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Condition: Thoracic
Intervention: Crizotinib; Not Applicable; Placebo; Xalkori (Crizotinib)
Open

CLINICAL TRIAL 18871
A Phase Ii, Open-Label, Multicenter, Single-Arm Study To Investigate TheEfficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage Ib, Ii, Iiia Or Selected Iiib Resectable And Untreated Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq)
Open

CLINICAL TRIAL 18494
A Phase I/II Study of Pembrolizumab and Vorinostat in Patients with Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC
Condition: Thoracic
Intervention: Pembrolizumab (Keytruda); SAHA (Vorinostat); Vorinostat; Zolinza (Vorinostat); suberoylanilide hydroxamic acid (Vorinostat)
Open

CLINICAL TRIAL 18923
A Multi-Center Open-Label Phase 1/2 Study of BGB324 in Combination with Erlotinib in Patients with Stage IIIb or Stage IV Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: BGB324; Erlotinib; Tarceva (Erlotinib)
Open

CLINICAL TRIAL 18811
Randomized, Double-Blind, Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)
Condition: Thoracic
Intervention: ADI-PEG 20; Alimta (Pemetrexed); Paraplatin (carboplatin); Pemetrexed; Placebo; carboplatin; cisplatin
Open

CLINICAL TRIAL 19101
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); BMS-986205; Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19082
A Phase I/Ib Trial of Pirfenidone Combined with Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Paraplatin (carboplatin); Pemetrexed; Pirfenidone; Taxol (paclitaxel); carboplatin; paclitaxel
Open

CLINICAL TRIAL 19293
Phase 1b/2 Study Of VX15/2503 In Combination With Avelumab In Advanced Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Avelumab; MSB00100718C (Avelumab); VX15/2503
Open

CLINICAL TRIAL 19406
Phase I/II Study of Nivolumab and Ipilimumab combined with Nintedanib in Non Small Cell Lung Cancer
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nintedanib; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 17969
Randomized Study of Erlotinib vs. Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: Erlotinib; Not Applicable; Placebo; Tarceva (Erlotinib)
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-033; TSR-042
Open

CLINICAL TRIAL 18321
Phase I/Ib trial of single agent PBF-509 and in combination with PDR001 for patients with advanced NSCLC
Condition: Thoracic
Intervention: PBF-509; PDR001
Open

CLINICAL TRIAL 17361
A Phase I/IB Trial of MEK162 in Combination with Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
Condition: Thoracic
Intervention: Erlotinib; MEK162; Tarceva (Erlotinib)
Open

CLINICAL TRIAL 19625
A Phase 1b Dose-Escalation Study Of TRC105 In Combination With Nivolumab In Patients With Metastatic Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); Carotuximab; Nivolumab; TRC105 (Carotuximab)
Open

CLINICAL TRIAL 19642
A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
Condition: Thoracic
Intervention: ABT-263 (Navitoclax); AZD9291 (Osimertinib); Navitoclax
Open

CLINICAL TRIAL 19163
Combination Immunotherapy with Ipilimumab and Nivolumab plus a Dendritic Cell based p53 Vaccine (Ad.p53-DC) in patients with relapsed Small Cell Lung Cancer (SCLC)
Condition: Thoracic
Intervention: Ad.p53 DC; BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19509
A Phase 1/2 Study Of Pegzilarginase (AEB1102, Co-Argi-PEG) In Combination With Pembrolizumab In The Treatment Of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Condition: Thoracic
Intervention: Pegzilarginase; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 19569
A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Non-small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: AMP-514 (Durvalumab); BI 1361849; CP-675,206 (tremelimumab); Durvalumab; MEDI4736 (Durvalumab); tremelimumab
Open

CLINICAL TRIAL 19619
Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination with Osimertinib in Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: AZD9291 (Osimertinib); G1T38; Osimertinib
Open

CLINICAL TRIAL 17971
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Condition: Thoracic
Intervention: Not Applicable
Open

CLINICAL TRIAL 19656
Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Condition: Thoracic
Intervention: Ceritinib (Zykadia); Taxotere (docetaxel); docetaxel
Open

CLINICAL TRIAL 19387
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)
Condition: Thoracic
Intervention: Poziotinib
Open

CLINICAL TRIAL 19694
Phase II Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); IMC-1121B (Ramucirumab); Nivolumab; Ramucirumab
Open

CLINICAL TRIAL 19389
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: JNJ-61186372
Open

CLINICAL TRIAL 19389
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: JNJ-61186372
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Saltos A, Khalil F, Smith M, Li J, Schell M, Antonia SJ, Gray JE. Clinical associations of mucin 1 in human lung cancer and precancerous lesions. Oncotarget. 2018 Nov;9(86):35666-35675. Pubmedid: 30479696. Pmcid: PMC6235019.
  • Dagogo-Jack I, Saltos A, Shaw AT, Gray JE. Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas. Am Soc Clin Oncol Educ Book. 2017 Nov;37:619-629. Pubmedid: 28561671.
  • Pan J, Saltos A, Smith D, Johnson A, Vossoughi J. Comparison of Respiratory Resistance Measurements Made with an Airflow Perturbation Device with Those from Impulse Oscillometry. J Med Eng. 2016 Mar;2013:165782. Pubmedid: 27006908. Pmcid: PMC4782682.
  • Koltz MT, Polifka AJ, Saltos A, Slawson RG, Kwok Y, Aldrich EF, Simard JM. Long-term outcome of Gamma Knife stereotactic radiosurgery for arteriovenous malformations graded by the Spetzler-Martin classification. J Neurosurg. 2013 Jan;118(1):74-83. Pubmedid: 23082882.
  • Smith DC, Schreiber KM, Saltos A, Lichenstein SB, Lichenstein R. Ambulatory cell phone injuries in the United States: an emerging national concern. J Safety Res. 2013 Dec;47:19-23. Pubmedid: 24237866.